SPARINGVISION

Milestone Pharmaceuticals reported Q3 2024 financials, focusing on potential FDA approval for CARDAMYST nasal spray for PSVT, with a PDUFA date set for March 27, 2025. The company also plans to initiate a Phase 3 trial for etripamil in AFib-RVR in H1 2025. Financial highlights include a net loss of $9.4 million for Q3 2024, with cash, cash equivalents, and short-term investments totaling $76.4 million as of September 30, 2024.